| Sneeuwvlok Score | |
|---|---|
| Waardering | 0/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 4/6 |
| Dividenden | 0/6 |
Frequency Therapeutics, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$14.98 |
| 52 Week Hoogtepunt | US$279.50 |
| 52 Week Laag | US$9.15 |
| Bèta | 0.77 |
| 11 maand verandering | -0.10% |
| 3 maanden verandering | -58.68% |
| 1 Jaar Verandering | -87.52% |
| 33 jaar verandering | -98.71% |
| 5 jaar verandering | n/a |
| Verandering sinds IPO | -97.81% |
Recent nieuws en updates
Recent updates
Is Frequency Therapeutics (NASDAQ:FREQ) Weighed On By Its Debt Load?
Jan 01
Frequency Therapeutics (NASDAQ:FREQ) Has Debt But No Earnings; Should You Worry?
Jan 19Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are Reducing Their Forecasts For This Year
Aug 18Health Check: How Prudently Does Frequency Therapeutics (NASDAQ:FREQ) Use Debt?
Jul 31Frequency Therapeutics (FREQ) Investor Presentation - Slideshow
Jun 18Frequency Therapeutics: A Look At What's Next After A Disappointing Data Readout
Apr 21Frequency Therapeutics, Inc. (NASDAQ:FREQ) Analysts Are More Bearish Than They Used To Be
Apr 04We're Not Worried About Frequency Therapeutics' (NASDAQ:FREQ) Cash Burn
Mar 15If You Had Bought Frequency Therapeutics (NASDAQ:FREQ) Shares A Year Ago You'd Have Earned 55% Returns
Jan 22Have Insiders Sold Frequency Therapeutics, Inc. (NASDAQ:FREQ) Shares Recently?
Dec 27Frequency Therapeutics to host investor event in early January next year
Dec 18How Much Are Frequency Therapeutics, Inc. (NASDAQ:FREQ) Insiders Taking Off The Table?
Dec 10Frequency Therapeutics, Inc. (NASDAQ:FREQ) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Nov 19Frequency Therapeutics EPS beats by $0.16, beats on revenue
Nov 16Frequency Therapeutics Is An Interesting Speculative Play Ahead Of Phase 2 Results
Nov 09Rendement voor aandeelhouders
| FREQ | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 29.1% | -0.4% | -1.2% |
| 1Y | -87.5% | 20.1% | 30.6% |
Rendement versus industrie: FREQ presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 20.1 % opleverde.
Rendement versus markt: FREQ presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 30.6 % opleverde.
Prijsvolatiliteit
| FREQ volatility | |
|---|---|
| FREQ Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: De aandelenkoers van FREQ is de afgelopen 3 maanden volatiel geweest.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van FREQ is het afgelopen jaar gedaald van 21% naar 12%, maar is nog steeds hoger dan 75% van de US -aandelen.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2014 | 47 | David Lucchino | www.frequencytx.com |
Frequency Therapeutics, Inc. Samenvatting
| FREQ fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$547.27m |
| Inkomsten(TTM) | -US$59.31m |
| Inkomsten(TTM) | n/a |
0.0x
P/S-verhouding-9.2x
Koers/WinstverhoudingIs FREQ overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| FREQ resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$0 |
| Kosten van inkomsten | US$42.02m |
| Brutowinst | -US$42.01m |
| Overige uitgaven | US$17.30m |
| Inkomsten | -US$59.31m |
Laatst gerapporteerde inkomsten
Sep 30, 2023
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -1.62 |
| Brutomarge | 0.00% |
| Nettowinstmarge | 0.00% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde FREQ op de lange termijn?
Bekijk historische prestaties en vergelijking